| Vigamox (U.S.N.L.M.) | |
|---|---|
| Dosing/ conjunctivitis | 1 drop tid for 7 days (See Moxeza for bid dosing) |
| Dosing/ corneal ulcer | In office loading dose then 2drops q15min for 2-3hr, then qhr, q3-4hr overnight (ung hs less severe cases), qhr day 2, then q2hr to significant resolution, then qid to day 14. |
| Chem Specs | moxifloxacin 0.5% |
| Quantities | 3 ml in 4ml bottle |
| Cost | 82.40 generic |
| Class | fourth-generation fluoroquinolone |
| Action | Binds bacterial DNA gyrase topoisomerase II and topoisomerase IV |
| Activity | Active against a very broad range of gram negative and positive organisms. Click heading for details in package insert. Active against a very broad range of gram negative and positive organisms. Click heading for details in package insert. |
| Usage | Indicated for bacterial conjunctivitis, off label for corneal ulcer. |
| Enhanced gram positive activity with bulky side chains which combat resistance and enhance potency. Superior time-kill characteristics. Better solubility in ophthalmic solution allows higher concentration. Biphasic molecule may explain enhanced corneal penetration. Enhanced gram positive activity with bulky side chains which combat resistance and enhance potency. Superior time-kill characteristics. Better solubility in ophthalmic solution allows higher concentration. Biphasic molecule may explain enhanced corneal penetration. |
|
| Contraindications | Hypersensitivity to Moxifloxacin, other quinolones or any components. |
| Pediatric use | The safety and effectiveness have been established in all ages. |
| Pregnancy | No adequate and well-controlled studies in pregnant women. Administration to pregnant rats, monkeys and rabbits did not produce adverse effects at clinically relevant doses. No adequate and well-controlled studies in pregnant women. Administration to pregnant rats, monkeys and rabbits did not produce adverse effects at clinically relevant doses. |
| Self preserved. Slight yellowish color. Ophthalmic patent expiration September 29, 2019. |